Biopharma Breakthrough: Examining Pfizer’s Strategic Seagen Acquisition

Pfizer Inc.’s acquisition of biotech firm Seagen Inc. at a staggering $43 billion highlights a pivotal shift in its oncology strategy, reflecting confidence in Seagen’s cutting-edge cancer therapies. This strategic move not only amplifies Pfizer’s presence in the pharmaceutical industry but also leverages Seagen’s innovative monoclonal antibody-based treatments. With regulatory approvals in place, Seagen is…